Vertex Pharmaceuticals (VRTX) Other Operating Expenses (2009 - 2026)

Vertex Pharmaceuticals has reported Other Operating Expenses for 18 years, with the latest figure at $393.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses fell 48.49% year-over-year to $393.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.8 billion (down 72.4% YoY), and the FY2025 full-year result was $2.2 billion, down 64.84% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $393.5 million, down from $523.4 million in the prior quarter.
• The five-year high for Other Operating Expenses was $4.8 billion in Q2 2024, with the low at $240.3 million in Q1 2022.
• Average Other Operating Expenses over 5 years is $682.0 million, with a median of $410.6 million recorded in 2025.
• Year-over-year, Other Operating Expenses surged 1052.09% in 2024 and plunged 91.48% in 2025.
• Tracing VRTX's Other Operating Expenses over 5 years: stood at $307.7 million in 2022, then rose by 9.03% to $335.5 million in 2023, then jumped by 51.92% to $509.7 million in 2024, then rose by 2.69% to $523.4 million in 2025, then dropped by 24.82% to $393.5 million in 2026.
• The last three Other Operating Expenses figures came in at $393.5 million (Q1 2026), $523.4 million (Q4 2025), and $467.4 million (Q3 2025), per Business Quant data.

Peer Comparison